The authors sought to compare the dosimetric quality of hypofractionated stereotactic radiosurgery in treating sizeable brain tumors across the following treatment platforms: GammaKnife (GK) Icon, CyberKnife (CK) G4, volumetric modulated arc therapy (VMAT) on the Varian TrueBeam STx, double scattering proton therapy (DSPT) on the Mevion S250, and intensity modulated proton therapy (IMPT) on the Varian ProBeam.
In this retrospective study, stereotactic radiotherapy treatment plans were generated for 10 patients with sizeable brain tumors (> 3 cm in longest diameter) who had been treated with VMAT. Six treatment plans, 20–30 Gy in 5 fractions, were generated for each patient using the same constraints for each of the following radiosurgical methods: 1) GK, 2) CK, 3) coplanar arc VMAT (VMAT-C), 4) noncoplanar arc VMAT (VMAT-NC), 5) DSPT, and 6) IMPT. The coverage; conformity index; gradient index (GI); homogeneity index; mean and maximum point dose of organs at risk; total dose volume (V) in Gy to the normal brain for 2 Gy (V2), 5 Gy (V5), and 12 Gy (V12); and integral dose were compared across all platforms.
Among the 6 techniques, GK consistently produced a sharper dose falloff despite a greater central target dose. GK gave the lowest GI, with a mean of 2.7 ± 0.1, followed by CK (2.9 ± 0.1), VMAT-NC (3.1 ± 0.3), and VMAT-C (3.5 ± 0.3). The highest mean GIs for the proton beam treatments were 3.8 ± 0.4 for DSPT and 3.9 ± 0.4 for IMPT. The GK consistently targeted the lowest normal brain volume, delivering 5 to 12 Gy when treating relatively smaller- to intermediate-sized lesions (less than 15–20 cm3). Yet, the differences across the 6 modalities relative to GK decreased with the increase of target volume. In particular, the proton treatments delivered the lowest V5 to the normal brain when the target size was over 15–20 cm3 and also produced the lowest integral dose to the normal brain regardless of the target size.
This study provides an insightful understanding of dosimetric quality from both photon and proton treatment across the most advanced stereotactic radiotherapy platforms.
BlonigenBJSteinmetzRDLevinLLambaMAWarnickREBrenemanJC: Irradiated volume as a predictor of brain radionecrosis after linear accelerator stereotactic radiosurgery. Int J Radiat Oncol Biol Phys77:996–10012010
CarminucciANieKRodrigoRWeinerJCohlerADanishS: Assessment of motion error for frame-based and noninvasive mask-based fixation using the Leksell Gamma Knife Icon radiosurgery system. J Neurosurg129 (Suppl 1):133–1392018
ChoiCYChangSDGibbsICAdlerJRHarshGR IVLiebersonRE: Stereotactic radiosurgery of the postoperative resection cavity for brain metastases: prospective evaluation of target margin on tumor control. Int J Radiat Oncol Biol Phys84:336–3422012
DingXLiXQinAZhouJYanDStevensC: Have we reached proton beam therapy dosimetric limitations? A novel robust, delivery-efficient and continuous spot-scanning proton arc (SPArc) therapy is to improve the dosimetric outcome in treating prostate cancer. Acta Oncol57:435–4372018
DongPPérez-AndújarAPinnaduwageDBraunsteinSTheodosopoulosPMcDermottM: Dosimetric characterization of hypofractionated Gamma Knife radiosurgery of large or complex brain tumors versus linear accelerator-based treatments. J Neurosurg125 (Suppl 1):97–1032016
GevaertTLevivierMLacornerieTVerellenDEngelsBReynaertN: Dosimetric comparison of different treatment modalities for stereotactic radiosurgery of arteriovenous malformations and acoustic neuromas. Radiother Oncol106:192–1972013
GrassbergerCTrofimovALomaxAPaganettiH: Variations in linear energy transfer within clinical proton therapy fields and the potential for biological treatment planning. Int J Radiat Oncol Biol Phys80:1559–15662011
LiWChoYBAnsellSLaperriereNMénardCMillarBA: The use of cone beam computed tomography for image guided Gamma Knife stereotactic radiosurgery: initial clinical evaluation. Int J Radiat Oncol Biol Phys96:214–2202016
MaLXiaPVerheyLJBoyerAL: A dosimetric comparison of fan-beam intensity modulated radiotherapy with Gamma Knife stereotactic radiosurgery for treating intermediate intracranial lesions. Int J Radiat Oncol Biol Phys45:1325–13301999
ManningMACardinaleRMBenedictSHKavanaghBDZwickerRDAmirC: Hypofractionated stereotactic radiotherapy as an alternative to radiosurgery for the treatment of patients with brain metastases. Int J Radiat Oncol Biol Phys47:603–6082000
MarshallTIChaudharyPMichaelidesováAVachelováJDavídkováMVondráčekV: Investigating the implications of a variable RBE on proton dose fractionation across a clinical pencil beam scanned spread-out Bragg peak. Int J Radiat Oncol Biol Phys95:70–772016
NaoiYKunishimaNYamamotoKYodaK: A planning target volume margin formula for hypofractionated intracranial stereotactic radiotherapy under cone beam CT image guidance with a six-degrees-of-freedom robotic couch and a mouthpiece-assisted mask system: a preliminary study. Br J Radiol87:201402402014
PrendergastBMDobelbowerMCBonnerJAPoppleRABadenCJMinnichDJ: Stereotactic body radiation therapy (SBRT) for lung malignancies: preliminary toxicity results using a flattening filter-free linear accelerator operating at 2400 monitor units per minute. Radiat Oncol8:2732013
ShawEScottCSouhamiLDinapoliRKlineRLoefflerJ: Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys47:291–2982000
TorrensMChungCChungHTHanssensPJaffrayDKemenyA: Standardization of terminology in stereotactic radiosurgery: report from the Standardization Committee of the International Leksell Gamma Knife Society: special topic. J Neurosurg121 Suppl:2–15 2014
TsaoMNRadesDWirthALoSSDanielsonBLGasparLE: Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol2:210–2252012
ZwahlenDRLangSHrbacekJGlanzmannCKloeckSNajafiY: The use of photon beams of a flattening filter-free linear accelerator for hypofractionated volumetric modulated arc therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys83:1655–16602012